Close Menu

NEW YORK – Findings from a randomized, Phase II clinical trial suggest adding bevacizumab (Genentech's Avastin) to erlotinib (Tarceva from Genentech/Astellas) treatment does not extend progression-free survival for patients with EGFR-mutated, non-small cell lung cancer (NSCLC) compared to erlotinib alone.

"Compared with erlotinib, the combination did not result in a significant difference in PFS," first and corresponding author Thomas Stinchcombe, a medical oncologist and investigator at the Duke Cancer Institute, and his colleagues wrote.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Genomics is a key element in the potential of precision medicine to transform oncology. 


This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 


This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Sponsored by

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.